The respiratory syncytial virus (RSV) vaccine produced strong immune responses in older adults during its first two seasons of use, according to a new study.

MRNA's competitive landscape, particularly against Pfizer, and higher forward P ... Considering vaccines for infectious diseases, PFE's RSV vaccine (Abrysvo) is already approved and competing ...

It's notable, however, that Arexvy's main rival in the RSV vaccine space – Pfizer's Abrysvo – held up much better in the third quarter, with sales slipping only around 5% to $356 million.

Pfizer's RSV vaccine Abrysvo – given to the mother during pregnancy – is also an option for protecting newborns and infants from RSV disease in the first six months of life. Nearly all ...

Please note that sales of Pfizer’s PFE RSV vaccine, Abrysvo, and GSK plc’s GSK RSV vaccine Arexvy also declined in the fourth quarter. This downtick can be attributed to the restrictive ...

Respiratory syncytial virus (RSV) is known to cause considerable respiratory infection-related morbidity and mortality worldwide.1,2 Estimates published in 2022 from the UK highlight the ...

The syndrome has cropped up as a side effect in trials for RSV vaccines like Pfizer’s Abrysvo and GSK’s Arexvy. The single case of Guillain-Barré syndrome in the mRNA-1403 trial is ...

The increasing adoption of biologics and injectable drugs is a significant driver for the Vial Adaptors for Reconstitution Drug Market. With the rising prevalence of chronic diseases such as ...

Technological Advancements and Market Expansion Continuous innovation in vial adaptor designs, including integrated filtration, dual-chamber systems, and compatibility with multiple vial sizes ...